IGIris Karina Gratz

Iris Karina Gratz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Iris Karina Gratz has a total of 232 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Harnessing skin-resident γδ T cells for immunotherapy in cutaneous squamous cell carcinoma

    by Giorgia Nasi, Leonie C. Schöftner, Lara Ronacher, Amalia Sophianidis, Julia Feiser, Teodora Aleksandrova, Oliver Nussbaumer, Andrew Hutton, Roland Zauner, Johanna Moser-Waxenecker, et al.

    Gamma delta (γδ) T cells are critical for tissue immune surveillance and their presence in tumors correlates with a favorable prognosis, highlighting their therapeutic potential. Although γδ T cells are abundant in the skin, their therapeutic value in skin cancer has remained largely unexplored due to challenges in isolating sufficient numbers of γδ T cells from human tissues and a lack of suitable preclinical models for skin cancer. Here, we are using innovative methods to expand human cutaneous γδ T cells ex vivo, enabling us to investigate their therapeutic potential in a human cutaneous squamous cell carcinoma (cSCC) mouse model. In this model, γδ T cells were specifically recruited to and maintained in the cSCC xenograft. These tumor-infiltrating cells exhibited an activated, cytotoxic phenotype and demonstrated effective antitumor activity in vivo. Collectively, our findings provide preclinical evidence supporting human skin–resident γδ T cells as a promising immunotherapeutic approach for treating skin cancers such as cSCC.

  • Open Access

    Transcriptome-guided drug repurposing identifies selumetinib for an aggressive epithelial cancer

    by Sonja Dorfer, Roland Zauner, Christina Guttmann-Gruber, Victoria Reichl, Michael Ablinger, Stefanie Gruner, Julia I. Hummel, Josefina Piñón Hofbauer, Ulrich Koller, Iris K. Gratz, et al.


  • T Cells Promote Distinct Transcriptional Programs of Cutaneous Inflammatory Disease in Keratinocytes and Dermal Fibroblasts

    by Hannah A. DeBerg, Mitch L. Fahning, Suraj R. Varkhande, James D. Schlenker, William P. Schmitt, Aayush Gupta, Archana Singh, Iris K. Gratz, Jeffrey S. Carlin, Daniel J. Campbell, et al.


  • Open Access

    T cells promote distinct transcriptional programs of cutaneous inflammatory disease in keratinocytes and dermal fibroblasts

    by Hannah A. DeBerg, Mitch L. Fahning, Suraj R. Varkhande, James D. Schlenker, William P. Schmitt, Aayush Gupta, Archana Singh, Iris K. Gratz, Jeffrey S. Carlin, Daniel J. Campbell, et al.

    T cells and structural cells coordinate appropriate inflammatory responses and restoration of barrier integrity following insult. Dysfunctional T cells precipitate skin pathology occurring alongside altered structural cell frequencies and transcriptional states, but to what extent different T cells promote disease-associated changes remains unclear. We show that functionally diverse circulating and skin-resident CD4 + CLA + T cell populations promote distinct transcriptional outcomes in human keratinocytes and fibroblasts associated with inflamed or healthy tissue. We identify T h 17 cell-induced genes in keratinocytes that are enriched in psoriasis patient skin and normalized by anti-IL-17 therapy. We also describe a CD103 + skin-resident T cell-induced transcriptional module enriched in healthy controls that is diminished during psoriasis and scleroderma and show that CD103 + T cell frequencies are altered during disease. Interrogating clinical data using immune-dependent transcriptional signatures defines the T cell subsets and genes distinguishing inflamed from healthy skin and allows investigation of heterogeneous patient responses to biologic therapy. GRAPHICAL


  • Open Access

    Challenges and progress related to gene editing in rare skin diseases

    by Josefina Piñón Hofbauer, Christina Guttmann-Gruber, Verena Wally, Anshu Sharma, Iris K. Gratz, Ulrich Koller


  • Top Cited Papers

    Regulatory T cells in skin mediate immune privilege of the hair follicle stem cell niche

    by Jarish N. Cohen, Victoire Gouirand, Courtney E. Macon, Margaret M. Lowe, Ian C. Boothby, Joshua M. Moreau, Iris K. Gratz, Angelika Stoecklinger, Casey T. Weaver, Arlene H. Sharpe, et al.

    Immune tolerance is maintained in lymphoid organs (LOs). Despite the presence of complex immune cell networks in non-LOs, it is unknown whether self-tolerance is maintained in these tissues. We developed a technique to restrict genetic recombination to regulatory T cells (T regs ) only in skin. Selective depletion of skin T regs resulted in T cell–mediated inflammation of hair follicles (HFs). Suppression did not rely on CTLA-4, but instead on high-affinity interleukin-2 (IL-2) receptor expression by skin T regs , functioning exclusively in a cell-extrinsic manner. In a novel model of HF stem cell (HFSC)–driven autoimmunity, we reveal that skin T regs immunologically protect the HFSC niche. Finally, we used spatial transcriptomics to identify aberrant IL-2 signaling at stromal-HF interfaces in a rare form of human alopecia characterized by HFSC destruction and alopecia areata. Collectively, these results reveal the fundamental biology of T regs in skin uncoupled from the systemic pool and elucidate a mechanism of self-tolerance.


  • Open Access

    Targeting of Th17-related cytokines in patients with Darier Disease

    by Monika Ettinger, Teresa Burner, Anshu Sharma, Yun-Tsan Chang, Angelika Lackner, Pacôme Prompsy, Isabella Pospischil, Judith Traxler, Gerald Wahl, Sabine Altrichter, et al.

    Darier disease (DD) is a rare, inherited multi-organ disorder associated with mutations in the ATP2A2 gene. DD patients often have skin involvement characterized by malodorous, inflamed skin and recurrent, severe infections. Therapeutic options are limited and inadequate for the long-term management of this chronic disease. Using gene and protein expression profiling assays, we demonstrate enhanced expression of Th-17-related genes and cytokines and increased numbers of Th17 cells in six DD patients. We prove that targeting the IL-23/-17 axis in DD with monoclonal antibodies is an effective and safe therapy for DD patients, leading to significant clinical improvement. As DD is a chronic, relapsing disease, our findings provide new options for the long-term management of skin inflammation in patients with DD.


  • Transcriptomic Profiling Identifies CD8+ T Cells in the Brain of Aged and Alzheimer’s Disease Transgenic Mice as Tissue-Resident Memory T Cells

    by Barbara Altendorfer, Michael Stefan Unger, Rodolphe Poupardin, Anna Hoog, Daniela Asslaber, Iris Karina Gratz, Heike Mrowetz, Ariane Benedetti, Diana Marisa Bessa de Sousa, Richard Greil, et al.

    Peripheral immune cell infiltration into the brain is a prominent feature in aging and various neurodegenerative diseases such as Alzheimer’s disease (AD). As AD progresses, CD8+ T cells infiltrate into the brain parenchyma, where they tightly associate with neurons and microglia. The functional properties of CD8+ T cells in the brain are largely unknown. To gain further insights into the putative functions of CD8+ T cells in the brain, we explored and compared the transcriptomic profile of CD8+ T cells isolated from the brain and blood of transgenic AD (APPswe/PSEN1dE9, line 85 [APP-PS1]) and age-matched wild-type (WT) mice. Brain CD8+ T cells of APP-PS1 and WT animals had similar transcriptomic profiles and substantially differed from blood circulating CD8+ T cells. The gene signature of brain CD8+ T cells identified them as tissue-resident memory (Trm) T cells. Gene Ontology enrichment and Kyoto Encyclopedia of Genes and Genomes pathway analysis on the significantly upregulated genes revealed overrepresentation of biological processes involved in IFN-β signaling and the response to viral infections. Furthermore, brain CD8+ T cells of APP-PS1 and aged WT mice showed similar differentially regulated genes as brain Trm CD8+ T cells in mouse models with acute virus infection, chronic parasite infection, and tumor growth. In conclusion, our profiling of brain CD8+ T cells suggests that in AD, these cells exhibit similar adaptive immune responses as in other inflammatory diseases of the CNS, potentially opening the door for immunotherapy in AD. Visual Abstract Key Points Brain CD8+ T cells of aged WT and APP-PS1 mice are identified as Trm T cells. Upregulated genes of brain CD8+ cells are involved in type I IFN signaling.


  • Open Access

    Therapy Development for Epidermolysis Bullosa

    by Josefina Piñón Hofbauer, Verena Wally, Christina Guttmann-Gruber, Iris Gratz, Ulrich Koller

    Although rare genodermatoses such as Epidermolysis bullosa have received more attention over the last years, no approved treatment options targeting causal mutations are currently available. Still, such diseases can be devastating, in some cases even associated with life-threatening secondary manifestations. Therefore, developing treatments that target disease-associated complications along with causal therapies remains the focus of current research efforts, in order to increase patient’s quality of life and potentially their life expectancy. Epidermolysis bullosa is a genodermatosis that is caused by mutations in either one of 16 genes, predominantly encoding structural components of the skin and mucosal epithelia that are crucial to give these barrier organs physical and mechanical resilience to stress. The genetic heterogeneity of the disease is recapitulated in the high variability of phenotypic expressivity observed, ranging from minor and localized blistering to generalized erosions and wound chronification, rendering certain subtypes a systemic disease that is complicated by a plethora of secondary manifestations. During the last decades, several studies have focused on developing treatments for EB patients and significant progress has been made, as reflected by numerous publications, patents, and registered trials available. Overall, strategies range from causal to symptom-relieving approaches, and include gene, RNA and cell therapies, as well as drug developments based on biologics and small molecules. In this chapter, we highlight the most recent and promising approaches that are currently being investigated in order to provide effective treatments for patients with epidermolysis bullosa in the future.


  • Open Access

    Cutting Edge: Tissue Antigen Expression Levels Fine-Tune T Cell Differentiation Decisions In Vivo

    by Douglas F. Pinheiro, Antal B. Szenes-Nagy, Megan M. Maurano, Melanie Lietzenmayer, Maria M. Klicznik, Raimund Holly, Daniel Kirchmeier, Sophie Kitzmueller, Gertrude Achatz-Straussberger, Michael D. Rosenblum, et al.

    Immune homeostasis in peripheral tissues is, to a large degree, maintained by the differentiation and action of regulatory T cells (Treg) specific for tissue Ags. Using a novel mouse model, we have studied the differentiation of naive CD4+ T cells into Foxp3+ Treg in response to a cutaneous Ag (OVA). We found that expression of OVA resulted in fatal autoimmunity and in prevention of peripheral Treg generation. Inhibiting mTOR activity with rapamycin rescued the generation of Foxp3+ T cells. When we varied the level of Ag expression to modulate TCR signaling, we found that low Ag concentrations promoted the generation of Foxp3+ T cells, whereas high levels expanded effector T cells and caused severe autoimmunity. Our findings indicate that the expression level of tissue Ag is a key determinant of the balance between tissue-reactive effector and peripheral Foxp3+ T cells, which determines the choice between tolerance and autoimmunity.